AGN 197.40 Allergan Inc $AGN Hit a 52 week high of 200.99 Closing the day 11/06/14 at 197.40 +1.08 +0.55% With a day low of 195.29 and a total volume of 3,718,726.
AGN Recent Posts: http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Hospira Beats on Earnings & Sales in Q3, Narrows Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:53PM CST
Hospira reported third-quarter 2014 adjusted earnings of 74 cents per share.
AGN: 197.40 (+1.08), ABAX: 53.84 (-0.61), ABBV: 62.71 (+0.17), HSP: 56.64 (+3.54)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 197.40 (+1.08), ACT: 250.38 (+2.47), MSFT: 48.70 (+0.84), VZ: 50.28 (-0.06)
Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 197.40 (+1.08), BIIB: 323.47 (+3.92), PRGO: 152.49 (-6.01), ABBV: 62.71 (+0.17)
Uptrend Call Working As Allergan Stock Rises 18.8% (AGN)
Comtex SmarTrend(R) - Thu Nov 06, 9:59AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 18.85% as of today's recent price of $198.60.
AGN: 197.40 (+1.08)
Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 197.40 (+1.08), ENDP: 70.19 (+1.49), AUXL: 33.27 (+0.61), ABBV: 62.71 (+0.17)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 197.40 (+1.08), VRX: 128.77 (-3.14), ACT: 250.38 (+2.47), SHPG: 199.95 (+1.34), ABBV: 62.71 (+0.17)
Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - Wed Nov 05, 7:01PM CST
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 197.40 (+1.08), ACT: 250.38 (+2.47), SWKS: 62.14 (+1.26), AKRX: 37.88 (-3.80), SLXP: 138.55 (-0.95), AAPL: 108.70 (-0.16)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 197.40 (+1.08), VRX: 128.77 (-3.14), ACT: 250.38 (+2.47)
New Survey Shows Nearly 60% Of Women Say They Would Rather Have A More Youthful Looking Face Than A More Youthful Looking Body(1)
PR Newswire - Wed Nov 05, 3:25PM CST
According to the results of a national survey conducted by Wakefield Research on behalf of Allergan, Inc., nearly 60% of women surveyed, ages 21-65 (n=500) say they'd rather have a more youthful looking face than a more youthful looking body1. Of the respondents, 64% noted that the shape of their face has changed as they have aged, and 44% have noticed a decrease in cheek volume or fullness in the past 10 years. Of women surveyed, 44% believe that if they lose volume in their cheek area, there is nothing they can do to correct it.1
AGN: 197.40 (+1.08)
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Business Wire - Wed Nov 05, 8:37AM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that Donald Pearl has joined the company as Vice President of Neurology. Mr. Pearl will work closely with senior leadership to build out the neurology commercial structure in the U.S. as Ipsen builds upon its 20 years of clinical experience with Dysport(R) (abobotulinumtoxinA) and pursues a comprehensive and ambitious neurotoxin clinical study program.
AGN: 197.40 (+1.08)
Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza
George Budwell, The Motley Fool - Motley Fool - Wed Nov 05, 8:36AM CST
Healthcare stocks, in general, and biopharmas, in particular, have seen some of their best returns in decades, fueled mainly by a wave of new drugs gaining approval and an aging population in the U.S. The growth story of specialty and generic...
AGN: 197.40 (+1.08), ACT: 250.38 (+2.47), TEVA: 58.72 (+0.93)
Pershing Square is Handed a Partial Win in Allergan Case
at The Street - Wed Nov 05, 8:14AM CST
Hedge fund can vote its shares at special shareholder meeting regarding Valeant bid, but may still face securities law claims.
AGN: 197.40 (+1.08), VRX: 128.77 (-3.14)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 197.40 (+1.08), BIIB: 323.47 (+3.92), VRX: 128.77 (-3.14), ACT: 250.38 (+2.47), JAZZ: 172.37 (+5.19), ALXN: 193.14 (+3.25), CELG: 107.14 (+1.99)
Top Funds Buy Ulta Beauty, Alexion, Avago
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Managers of leading mutual funds in recent months have continued to stock up on large medical stocks, such as Illumina (ILMN), Alexion Pharmaceuticals (ALXN), Celgene (CELG), Jazz Pharmaceuticals (JAZZ),Allergan (AGN) and Centene (CNC). The...
AMBA: 46.01 (+1.30), MNST: 100.48 (+1.31), SWKS: 62.14 (+1.26), GMCR: 153.06 (+2.60), ILMN: 189.87 (+3.50), WSM: 65.93 (+1.20), NXPI: 73.47 (+0.11), CELG: 107.14 (+1.99), HAIN: 107.84 (+2.18), AGN: 197.40 (+1.08), CNC: 93.56 (+1.07), V: 250.09 (+0.56), CALM: 43.12 (+1.21), JAZZ: 172.37 (+5.19), ALXN: 193.14 (+3.25), LOW: 57.57 (+0.63), ULTA: 122.08 (+3.42), MA: 85.75 (-0.24), AVGO: 87.63 (+0.92), PETM: 71.64 (+1.24)
Allergan takeover closer?
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Valeant's (VRX) hostile takeover of the Botox maker may be closer now that a federal judge denied Allergan's (AGN) request to stop activist investor Bill Ackman and his Pershing Square Capital Management from voting against board members opposed to...
AGN: 197.40 (+1.08), VRX: 128.77 (-3.14)
Bristol-Myers Signs Option Deal to Acquire Galecto Biotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:30PM CST
Bristol-Myers Squibb Company (BMY) and Denmark-based Galecto Biotech AB announced that both companies have entered into an agreement whereby Bristol-Myers Squibb will have an exclusive option to acquire Galecto Biotech AB.
AGN: 197.40 (+1.08), ABBV: 62.71 (+0.17), TEVA: 58.72 (+0.93), BMY: 58.46 (+0.64)
After Yesterday's Rally of 1.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Nov 04, 3:52PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $189.47 to a high of $196.54. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $193.63 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 197.40 (+1.08)
Allergan Comments on California Federal Court Ruling in Insider Trading Lawsuit against Valeant & Pershing Square
Business Wire - Tue Nov 04, 12:56PM CST
--Court Orders Valeant and Pershing Square to Correct Disclosures; Parties Enjoined from Voting Until Corrective Disclosures are Made
AGN: 197.40 (+1.08)
Video: Top 3 Earnings Reports To Watch Wednesday
at Investor's Business Daily - Tue Nov 04, 12:45PM CST
Several highly rated tech companies and drugmakers are set to report earnings on Wednesday. Here's a look at what analysts expect. Actavis (ACT) reports its results before the open. The specialty-drug giant is projected to earn $3.10 a share, a 48%...
AGN: 197.40 (+1.08), TSLA: 241.22 (+10.25), VRX: 128.77 (-3.14), ACT: 250.38 (+2.47), ATHM: 45.23 (+1.15)
Valeant And Pershing Square May Vote At Special Meeting
CNW Group - Tue Nov 04, 12:27PM CST
Today, the United States District Court for the Central District of California held that Pershing Square Capital Management, L.P., Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and related parties may vote shares of Allergan, Inc. (NYSE: AGN) or proxies at the upcoming December 18 stockholder meeting. Allergan had sought to disenfranchise its largest shareholder, PS Fund 1, along with other shareholders solicited by PS Fund 1, by seeking an injunction to prevent them from voting at Allergan's December 18 special meeting. Today's ruling by Judge David O. Carter means that all Allergan shareholders, including PS Fund 1, will be permitted to have their voices heard by voting at the special meeting.
AGN: 197.40 (+1.08), VRX: 128.77 (-3.14), VRX.TO: 147.18 (-2.87)
AGN Recent Posts: http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Hospira Beats on Earnings & Sales in Q3, Narrows Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:53PM CST
Hospira reported third-quarter 2014 adjusted earnings of 74 cents per share.
AGN: 197.40 (+1.08), ABAX: 53.84 (-0.61), ABBV: 62.71 (+0.17), HSP: 56.64 (+3.54)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 197.40 (+1.08), ACT: 250.38 (+2.47), MSFT: 48.70 (+0.84), VZ: 50.28 (-0.06)
Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 197.40 (+1.08), BIIB: 323.47 (+3.92), PRGO: 152.49 (-6.01), ABBV: 62.71 (+0.17)
Uptrend Call Working As Allergan Stock Rises 18.8% (AGN)
Comtex SmarTrend(R) - Thu Nov 06, 9:59AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 18.85% as of today's recent price of $198.60.
AGN: 197.40 (+1.08)
Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 197.40 (+1.08), ENDP: 70.19 (+1.49), AUXL: 33.27 (+0.61), ABBV: 62.71 (+0.17)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 197.40 (+1.08), VRX: 128.77 (-3.14), ACT: 250.38 (+2.47), SHPG: 199.95 (+1.34), ABBV: 62.71 (+0.17)
Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - Wed Nov 05, 7:01PM CST
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 197.40 (+1.08), ACT: 250.38 (+2.47), SWKS: 62.14 (+1.26), AKRX: 37.88 (-3.80), SLXP: 138.55 (-0.95), AAPL: 108.70 (-0.16)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 197.40 (+1.08), VRX: 128.77 (-3.14), ACT: 250.38 (+2.47)
New Survey Shows Nearly 60% Of Women Say They Would Rather Have A More Youthful Looking Face Than A More Youthful Looking Body(1)
PR Newswire - Wed Nov 05, 3:25PM CST
According to the results of a national survey conducted by Wakefield Research on behalf of Allergan, Inc., nearly 60% of women surveyed, ages 21-65 (n=500) say they'd rather have a more youthful looking face than a more youthful looking body1. Of the respondents, 64% noted that the shape of their face has changed as they have aged, and 44% have noticed a decrease in cheek volume or fullness in the past 10 years. Of women surveyed, 44% believe that if they lose volume in their cheek area, there is nothing they can do to correct it.1
AGN: 197.40 (+1.08)
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Business Wire - Wed Nov 05, 8:37AM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that Donald Pearl has joined the company as Vice President of Neurology. Mr. Pearl will work closely with senior leadership to build out the neurology commercial structure in the U.S. as Ipsen builds upon its 20 years of clinical experience with Dysport(R) (abobotulinumtoxinA) and pursues a comprehensive and ambitious neurotoxin clinical study program.
AGN: 197.40 (+1.08)
Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza
George Budwell, The Motley Fool - Motley Fool - Wed Nov 05, 8:36AM CST
Healthcare stocks, in general, and biopharmas, in particular, have seen some of their best returns in decades, fueled mainly by a wave of new drugs gaining approval and an aging population in the U.S. The growth story of specialty and generic...
AGN: 197.40 (+1.08), ACT: 250.38 (+2.47), TEVA: 58.72 (+0.93)
Pershing Square is Handed a Partial Win in Allergan Case
at The Street - Wed Nov 05, 8:14AM CST
Hedge fund can vote its shares at special shareholder meeting regarding Valeant bid, but may still face securities law claims.
AGN: 197.40 (+1.08), VRX: 128.77 (-3.14)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 197.40 (+1.08), BIIB: 323.47 (+3.92), VRX: 128.77 (-3.14), ACT: 250.38 (+2.47), JAZZ: 172.37 (+5.19), ALXN: 193.14 (+3.25), CELG: 107.14 (+1.99)
Top Funds Buy Ulta Beauty, Alexion, Avago
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Managers of leading mutual funds in recent months have continued to stock up on large medical stocks, such as Illumina (ILMN), Alexion Pharmaceuticals (ALXN), Celgene (CELG), Jazz Pharmaceuticals (JAZZ),Allergan (AGN) and Centene (CNC). The...
AMBA: 46.01 (+1.30), MNST: 100.48 (+1.31), SWKS: 62.14 (+1.26), GMCR: 153.06 (+2.60), ILMN: 189.87 (+3.50), WSM: 65.93 (+1.20), NXPI: 73.47 (+0.11), CELG: 107.14 (+1.99), HAIN: 107.84 (+2.18), AGN: 197.40 (+1.08), CNC: 93.56 (+1.07), V: 250.09 (+0.56), CALM: 43.12 (+1.21), JAZZ: 172.37 (+5.19), ALXN: 193.14 (+3.25), LOW: 57.57 (+0.63), ULTA: 122.08 (+3.42), MA: 85.75 (-0.24), AVGO: 87.63 (+0.92), PETM: 71.64 (+1.24)
Allergan takeover closer?
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Valeant's (VRX) hostile takeover of the Botox maker may be closer now that a federal judge denied Allergan's (AGN) request to stop activist investor Bill Ackman and his Pershing Square Capital Management from voting against board members opposed to...
AGN: 197.40 (+1.08), VRX: 128.77 (-3.14)
Bristol-Myers Signs Option Deal to Acquire Galecto Biotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:30PM CST
Bristol-Myers Squibb Company (BMY) and Denmark-based Galecto Biotech AB announced that both companies have entered into an agreement whereby Bristol-Myers Squibb will have an exclusive option to acquire Galecto Biotech AB.
AGN: 197.40 (+1.08), ABBV: 62.71 (+0.17), TEVA: 58.72 (+0.93), BMY: 58.46 (+0.64)
After Yesterday's Rally of 1.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Nov 04, 3:52PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $189.47 to a high of $196.54. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $193.63 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 197.40 (+1.08)
Allergan Comments on California Federal Court Ruling in Insider Trading Lawsuit against Valeant & Pershing Square
Business Wire - Tue Nov 04, 12:56PM CST
--Court Orders Valeant and Pershing Square to Correct Disclosures; Parties Enjoined from Voting Until Corrective Disclosures are Made
AGN: 197.40 (+1.08)
Video: Top 3 Earnings Reports To Watch Wednesday
at Investor's Business Daily - Tue Nov 04, 12:45PM CST
Several highly rated tech companies and drugmakers are set to report earnings on Wednesday. Here's a look at what analysts expect. Actavis (ACT) reports its results before the open. The specialty-drug giant is projected to earn $3.10 a share, a 48%...
AGN: 197.40 (+1.08), TSLA: 241.22 (+10.25), VRX: 128.77 (-3.14), ACT: 250.38 (+2.47), ATHM: 45.23 (+1.15)
Valeant And Pershing Square May Vote At Special Meeting
CNW Group - Tue Nov 04, 12:27PM CST
Today, the United States District Court for the Central District of California held that Pershing Square Capital Management, L.P., Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and related parties may vote shares of Allergan, Inc. (NYSE: AGN) or proxies at the upcoming December 18 stockholder meeting. Allergan had sought to disenfranchise its largest shareholder, PS Fund 1, along with other shareholders solicited by PS Fund 1, by seeking an injunction to prevent them from voting at Allergan's December 18 special meeting. Today's ruling by Judge David O. Carter means that all Allergan shareholders, including PS Fund 1, will be permitted to have their voices heard by voting at the special meeting.
AGN: 197.40 (+1.08), VRX: 128.77 (-3.14), VRX.TO: 147.18 (-2.87)
